MaaT Prepares For EMA Filing, US Expansion After Positive GVHD Readout

 
• By Alaric DeArment

The French biotech plans to file for EMA approval in graft-versus-host disease in mid-2025 while starting a US Phase III trial, which the CEO said in an interview is contingent on financing.

gvhd concept words isometric 3d word text concept with some related text and dot connected - vector
• Source: Shutterstock

More from Immunological

More from Anticancer